Association of Fetal Growth Restriction With Neurocognitive Function After Repeated Antenatal Betamethasone Treatment vs Placebo: Secondary Analysis of the ACTORDS Randomized Clinical Trial.

ABSTRACT:

Importance

Repeated doses of antenatal betamethasone are recommended for women at less than 32 weeks' gestation with ongoing risk of preterm birth. However, concern that this therapy may be associated with adverse neurocognitive effects in children with fetal growth restriction (FGR) remains.

Objective

To determine the influence of FGR on the effects of repeated doses of antenatal betamethasone on neurocognitive function in midchildhood.

Design, setting, and participants

This preplanned secondary analysis of data from the multicenter Australasian Collaborative Trial of Repeat Doses of Corticosteroids (ACTORDS) included women at less than 32 weeks' gestation with ongoing risk of preterm birth (<32 weeks) at least 7 days after an initial course of antenatal corticostero

SUBMITTER: Cartwright RD 

PROVIDER: S-EPMC6484607 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature